Recent

% | $
Quotes you view appear here for quick access.

Passport Potash Inc. Message Board

helpme_hanna 196 posts  |  Last Activity: 8 hours ago Member since: Jul 26, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • helpme_hanna helpme_hanna 8 hours ago Flag

    I sure wish the recent options grant had a higher strike price. Anyway, it is good to see Curtis Lockshin and other directors exercising their .29 options--and the dilution is minimal, way less than 1% even if Geert exercises his 133,000.

    So helpme_hanna

  • helpme_hanna helpme_hanna 19 hours ago Flag

    gizmo_puppy you are wrong. Here's a quote from the September Chemistry World journal:

    "An increasing number of acquisitions are also occurring at Phase II clinical trial stage, or even earlier, before products have been approved by regulators. This was seen with Alexion Pharmaceuticals’ $8.4 billion acquisition of rare diseases firm Synageva BioPharma, which has no approved products on the market."

    So helpme_hanna

  • There have been posters here that say large biotech firms are pretty much uninterested in acquiring firms who have not proven their major products by getting them approved and have actually marketed them for six months or so.

    Fortunately, the above view is simply false. Here is an example, taken from the September issue of Chemistry World:

    "An increasing number of acquisitions are also occurring at Phase II clinical trial stage, or even earlier, before products have been approved by regulators. This was seen with Alexion Pharmaceuticals’ $8.4 billion acquisition of rare diseases firm Synageva BioPharma, which has no approved products on the market."

    Whether or not Rxi is bought out for a reasonable price (which would be $6-$10 per share, I think) is yet to be seen. However, we do know that Rxi is not necessarily road kill just because it has not taken sd-rxrnai all the way to market.

    So helpme_hanna

  • helpme_hanna helpme_hanna Feb 12, 2016 12:14 PM Flag

    Geert will not let it just dribble away. It's too valuable. He could buy it himself, take it private and go from there if necessary. But that won't be necessary. Rxi will survive and we will make money. Keep in mind that there is no debt; therefore, Geert is under a lot less pressure than if there were a loan to pay off.

    So helpme_hanna

  • Reply to

    Gazprom / Destination Flexibility

    by brbking Feb 11, 2016 5:42 PM
    helpme_hanna helpme_hanna Feb 12, 2016 9:38 AM Flag

    The latest conference call by the company, and the information on its website, says that the demand for lng shipping will increasingly outstrip the supply of ships. Also, dlng is about the only fleet with ice capable vessels, which will be increasingly important as northern routes open up.

    Go do some due diligence at the company website. I did and have loaded up quite a bit.

    So helpme_hanna

  • helpme_hanna helpme_hanna Feb 11, 2016 9:45 PM Flag

    "Biotech out of favor at the time being."

    Yeah, dang it. Just our luck that things seem to be looking up in the lab when everybody with the money is looking elsewhere. Geert's salesmanship will be put to the test now--he cannot sit around for another year or two years and just wait for the science to sell itself. He must get at least some money based upon what he has already accomplished--which might look to some to be fairly little but which I think he can spin as quite a lot.

    It is not just about the science--it is about whether or not Geert can convince the right people that the science is what it purports to be, without a lot of proof at this time.

    So helpme_hanna

  • Reply to

    Why selling off?

    by petermelz Feb 11, 2016 11:59 AM
    helpme_hanna helpme_hanna Feb 11, 2016 1:53 PM Flag

    It's panic selling and herd mentality. This is a small cap company with a very small float. If some investor(s) want to get out because of a panic attack, they will knock the price way down.

    Tomorrow (Friday) is dividend payment day and if you reinvest your dividends (I do) you will do so tomorrow at a very good price.

    So helpme_hanna

  • It might well be the case that Rxi will not get a really big deal--will not be bought out for $2 billion or $3 billion--until it validates sd-rxrnai a lot more. We will need some good, early p3 results for nasty scarring, some initial good clinical results for corneal scarring, an indication that we are getting ready to move to market with skin cosmetics, good p3 interim results on Samcyprone.

    Let's say Rxi will need $15 million per year for to get from Feb. 2017 to Feb. 2020 (there is already enough money to get to Feb. 2017.) That's a total of $45 million needed. That is not huge in terms of biotech. It is less than 20% of what OPKO recently got for just one of its products.

    rmsacc and others have talked about the need for big biotechs to but cutting edge technologies because they cannot afford to develop them from scratch. Well, here's a chance to get a toe hold for virtually peanuts.
    Of course we are not through p3 tests yet, but neither are we totally without data and neither are we in need of much money to get way up the road.

    Maybe a big pharma would see its way to front the $45 million for some sort of option deal at at a much higher price. This is potentially cutting edge technology and it has more than a little validation. Seems worth $45 million in seed money to me.

    So helpme_hanna

  • helpme_hanna helpme_hanna Feb 10, 2016 7:37 PM Flag

    C'mon sabaidii, give it a rest. Every time rmsacc posts anything you berate and insult him. It is true that Rxi needs money. It is also true that there are positive and hopeful things going on. My view is that there is enough, more than enough, positive things--and big enough potential markets--to think Rxi will likely get the relatively small amount of cash it needs to operate until 2018 or more.

    I might be wrong but I don't think my view is stupid or just dismissable out of hand--and my view is pretty much in line with rmsacc.

    So helpme_hanna

  • helpme_hanna helpme_hanna Feb 10, 2016 2:54 PM Flag

    grabbngo,

    I absolutely agree with you that Rxi will succeed and even flourish. There is way too much good stuff going on for it not to do so. I do not, however, think that May is in anyway the drop dead date. If there is not a price move to $1+ by early May, we will be delisted from Nasdaq. So what? The Nasdaq listing has been of no help anyway.

    The key is the interest of bigger pharma in either buying the company whole or making some deal(s) with Rxi. They will do that if they are convinced that the technology if good and that it will make money for them--and there will be such a conviction, I am sure. The last thing buyers or deal makers give a rat's behind about is where the stock is trading.

    So helpme_hanna

  • "MirImmune chose sd-RNAi because it is the only RNAi technology that doesen't negatively affect cell growth"

    So helpme_hanna

  • Reply to

    This was best presentation yet, by far

    by helpme_hanna Feb 9, 2016 3:54 PM
    helpme_hanna helpme_hanna Feb 9, 2016 6:55 PM Flag

    "Looks like Geert's 'well thought out plan' isn't working too well."

    It does look that way and that might be the case. We don't really know, though, what might be going on. I do think there have been nibbles and I am still fairly optimistic that enough money to last until late 2018 or even 2019 will be found in the next several months.

    Geert is in a very tough situation. He desperately wants to avoid giving too much away for too little but he needs money. I think he could get enough right now to operate for three or four years but he would just about have to give the store away to get it. He is holding out for a better deal, I think. I'm thinking he might just pull it off.

    So helpme_hanna

  • Reply to

    This was best presentation yet, by far

    by helpme_hanna Feb 9, 2016 3:54 PM
    helpme_hanna helpme_hanna Feb 9, 2016 6:14 PM Flag

    The delivery today was good. Geert does have a thick accent and will never be as easy for us to understand as a native speaker but it was a LOT better than earlier presentations. It is not only the science that will propel Rxi. It is the science along with an effective explanation of the science and why and how it will be commercially valuable. It takes marketing as well as just "science," imo. There are myriads of shuttered biotechs that had good science but couldn't get funding because nobody believed in the science or could see how to make money with it.

    So helpme_hanna

  • It was very clear and easy to understand. It contained more detail and explanation of the potential. It even spotlighted the quick progress that Mirlmmune is making with its license deal.

    I don't know if this will bring in more deals, with or without upfront money, but it certainly was an impressive performance. Maybe Geert hit his stride just in the knick of time.

    So helpme_hanna

  • Reply to

    Just in today.

    by woodstocklives Feb 8, 2016 6:06 PM
    helpme_hanna helpme_hanna Feb 8, 2016 9:31 PM Flag

    How small is the position you took in this stock? Smaller than a breadbox?

    So helpme_hanna

  • Anybody?

    So helpme_hanna

  • helpme_hanna helpme_hanna Feb 6, 2016 7:26 AM Flag

    "The current share price is $0.28 - $0.31 so why would they want to pay more?"

    They don't want to pay more and they might expect the company to fail altogether; however, if the market price does (surprisingly and contrary to what they now expect) go above the option strike price, they want to be able to exercise their options. They couldn't do that if so exercising resulted in their having more than 4.99%.

    As to lack of insider buying, I agree that does speak volumes.

    So helpme_hanna

  • Reply to

    Grim? I guess. Obviously roadkill? No.

    by helpme_hanna Feb 5, 2016 12:55 PM
    helpme_hanna helpme_hanna Feb 5, 2016 4:56 PM Flag

    student_of_history_55,

    It's not fear of dilution that is keeping investors and insiders away, imo. All would-be-investors know that the company needs cash big time and will have to pay for that cash through dilution or out-llicensing away assets. What is keeping investors and insiders away is a belief either that the technology will not work or that the company will not be able to get the money it needs, or both, imo.

    So helpme_hanna

  • The chart is bad. The volume is minuscule. The current money situation is ominous--without more cash, the company would have to close up shop after this year. There are no clinical results beyond the three month time frame, which is way too little to draw any conclusions. Pretty grim, right?

    Here's the flip side. The stock is currently priced to reflect the view that the company is roadkill. If there is just about ANY intrinsic value to the company from sd-rxrnai or Samcyprone, it would far exceed the current market cap. There are a number of months left to substantiate some claims about the technology and to convince some potential partner or buyer of its value. Grim? I guess. Worth the risk at this price? I think so.

    Columbus took a chance, why not you?

    So helpme_hanna

  • Reply to

    Let the short squeeze begin!

    by helpme_hanna Feb 4, 2016 11:18 AM
    helpme_hanna helpme_hanna Feb 4, 2016 1:06 PM Flag

    "A short squeeze is just brief entertainment, whereas (real, fundamental) buying interest is how you make money."

    A person can make real money with a short squeeze too. With the squeezed printing stock I mentioned above, I bought puts right at the money when the stock was $100. The puts cost me $6 each and I bought 2 contracts [=200 puts.] I sold the puts when the stock--which eventually went bankrupt--fell back to $5 p/s. My 200 puts brought me $95 each for a net of $89 each, or a total net of $17,800 on a purchase of two contracts which had cost me a total of $1200.

    The above was made possible because of a squeeze. If RXII gets squeezed to $6, and maybe less, I will cash out and will not worry about "real, fundamental buying interest."

    So helpme_hanna

PPRTF
0.00110.0000(0.00%)Feb 8 3:41 PMEST